Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, Lecanemab
Frontage Laboratories announced a collaboration with Eisai and Biogen to support the bioanalysis of lecanemab (BAN2401) in a phase 3 study for Alzheimer's disease.
The study met aggressive timelines, showcasing Frontage's commitment to addressing medical needs. Notably, the study has delivered favorable results as highlighted in a presentation on November 29, 2022.
Frontage's scientific team contributed to biomarker analysis, reinforcing their role in global clinical research.
- Collaboration with Eisai and Biogen enhances Frontage's reputation in the Alzheimer's treatment space.
- Successful completion of bioanalytical support for the lecanemab study may lead to future contracts and collaborations.
- Favorable results from the phase 3 study can lead to increased demand for Frontage's services.
- None.
EXTON, Pa., Dec. 12, 2022 /PRNewswire/ -- Frontage's Bioanalytical team partnered with Eisai/Biogen to support the PK and PD biomarker bioanalysis of lecanemab (BAN2401) in their investigational global phase 3 study in US and China. Recently Eisai/Biogen publicly shared the favorable results of the lecanemab (BAN2401) Clarity AD study which Eisai presented on November 29, 2022, at the Clinical Trials on Alzheimer's Disease Congress (CTAD), and published the findings in NEJM. The Frontage team developed and validated the LC-MS-based PK method back in 2010 and provided bioanalytical support to this program from clinical Phase 1 to the late phase trial. Frontage's scientific team also provided biomarker analysis (p-Tau181, NfL, and GFAP) for this Phase 3 study and met the very aggressive timelines of data lock. What Eisai/Biogen have achieved offers real hope to the patient, their families, and all the people who care about them.
"Here at Frontage, we also celebrated this news because it's a powerful reminder of the reason we are in this field–to work towards combating disease and positively improving the lives of others. We are very proud to have worked closely with our Eisai partners to support the bioanalysis of lecanemab (BAN2401) in this large global phase 3 study. We are extremely proud to be a part of the team and hope to contribute to the unmet medical needs of patients with Alzheimer's disease," announces John Lin, Frontage's EVP and Global Head, Bioanalytical and Biologics Services.
About Frontage (www.frontagelab.com)
Frontage Holdings Corp (1521.HK), together with its wholly owned subsidiary Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) that provides integrated, science-driven, product development services from drug discovery to late-phase clinical process to enable biopharmaceutical companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment, and early-phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions. For more details visit www.frontagelab.com.
Contact: Bryan Newman, bnewman@frontagelab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/frontage-partners-with-eisai-and-biogen-to-complete-the-clarity-ad-study-for-the-alzheimers-drug-lecanemab-301699008.html
SOURCE Frontage Laboratories, Inc.
FAQ
What is the partnership between Frontage and Eisai/Biogen about?
What are the results of the lecanemab Clarity AD study?
When was the news about Frontage's collaboration announced?
How does Frontage support Alzheimer's research?
What is the significance of the lecanemab study for Frontage?
